Yesterday, PatientView released the results of its latest “Pharmaceutical Sector Corporate Reputation” survey. For Italy, the survey collected data from 103 groups of 
resident patients regarding the performance of the pharmaceutical industry during 2021. The 66% of Italian patient groups in 2021 rated the reputation of the pharmaceutical industry “Excellent” or “Good”
PatientView – September 22, 2022
In the Corporate Reputation of Pharma 2021, thousands of patient and healthcare professional groups shared their perspectives on how individual pharmaceutical companies and the industry as a whole performed in 2021.
Few studies explore the views of patient groups around the world about whether pharmaceuticals are meeting their expectations (and, if not, how they might improve the industry and individual pharmaceutical companies). PatientView's Corporate Reputation of Pharma provides healthcare professionals and patient advocacy groups with an opportunity to comment on the performance of the pharmaceutical industry, especially during the pandemic.
In its 11th year, The Corporate Reputation of Pharma survey had a record number of responses, with a total of 2,150 patient advocacy groups taking part in the review of a total of 47 companies.
That's sixteen reports published this year based on responses from patient groups collected in the November 2021-February 2022 survey.
The seven therapeutic areas evaluated:
■ Autoimmune conditions [including testing for individual autoimmune diseases]; ■ Cancer [including analyzes for individual cancers]; ■ HIV/AIDS; ■ Mental health; ■ Neuroscience [including analyzes for single neurological diseases]; ■ Rare diseases [including bleeding disorders]; and ■ Respiratory.
Nine geographic regions:
■ Asia [including country analysis]; ■Canada; ■ France; ■ Germany; ■ global; ■ Italy; ■Spain;■United Kingdom; and ■ United States.
Each report contains the following data:
- Insights into patient group relationships with the pharmaceutical industry at large, 2021 v. 2020;
- Pharmaceutical company rankings in 2021 (vs. 2020) as assessed by patient groups both “familiar with” and “working with” companies;
- Rankings of “big-pharma” companies in 2021 (vs. 2020) as assessed by patient groups both “familiar” and “workers” with companies;
- “Generic Pharma” Company Rankings, 2021 (v. 2020), as assessed by patient groups familiar with and working with companies;
- Company profiles compared 2021 with 2020;
- Comments from patient group respondents.
The patient groups that responded to this year's survey are located in Western Europe, North America, Central and Latin America, and Asia.
These patient groups participated in the survey from November 1, 2021 to March 1, 2022. The full results are published in report a of April 2022.
Similar to previous years, the pharmaceutical industry and the 47 companies mentioned were assessed for their performance on various indicators, from transparency to patient safety, all from the perspective of patient groups.
As the Covid-19 pandemic continues to shape the thinking of patients and patient groups about the pharmaceutical sector, questions on the subject are included in the 2021 survey (as in 2020).
Companies purchasing the report can use the research to identify patient-relevant strengths and weaknesses in their business. Companies can use this information to improve efforts to be more patient-centric in their operations
In summary, the Italian edition
The overall reputation of the pharmaceutical industry in Italy is strong and generally improving. After a very difficult first year of Covid-19, the industry has reacted well in Italy to the challenge of the pandemic and is positioned, from the point of view of the patients, above the comparison nations. However, reflecting significant statutory reform, patient groups in Italy would like to see improvements in equity in pharmacy pricing policies, as well as greater transparency in both pricing and pharmaceutical financing by stakeholders. Additionally, Italian patient groups strongly believe in the need for greater patient inclusion in all aspects of research and development.
COMPANY RANKING IN ITALY 2021
- The top three pharmaceutical companies in Italy in 2021, out of 22 companies, ranked by their overall corporate reputation (assessed by groups of Italian patient respondents familiar with the company): Roche, 1a | Novo Nordisk, 2nd | Pfizer, 3rd.
- Top three pharmaceutical companies in Italy in 2021, out of 6 companies, ranked by their overall corporate reputation (assessed by surveyed Italian patient groups working with the company): Pfizer, 1a | Roche, 2nd | Novarti, 3rd.
- The top three "big-pharma" companies in Italy in 2021, out of 12 "big-pharma" companies, ranked by their overall corporate reputation (assessed by groups of Italian patient respondents who are familiar with the company): Roche, 1st | Pfizer, 2nd | GSK, 3rd.
- The top three “big pharmaceutical” companies in Italy in 2021, out of 5 “big pharmaceutical” companies, ranked by their overall corporate reputation (assessed by groups of Italian patient respondents who work with the company): Pfizer, 1st | Roche, 2nd | Novarti, 3rd.
- The pharmaceutical companies that have risen the most in the Italian rankings, from 2020 to 2021, can be seen in the graph below.
Graph 5: Pharmaceutical companies that make the biggest rises in the Italian rankings, from 2020 to 2021, according to the assessment of the Italian patient groups interviewed who are familiar with the company
Rooms listed top to bottom, left to right
Companies assessed in terms of corporate reputation in the 2021 survey for Italy
AbbVie I AstraZeneca I Bayer I Biogen I Boehringer Ingelheim I Bristol Myers Squibb I Chiesi Farmaceutici I Eli Lilly I Gilead Sciences I GSK I Janssen I Menarini I MSD I Mylan I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Takeda I Teva
Results at the level of the pharmaceutical industry
The 66% of Italian patient groups in 2021 rated the reputation of the pharmaceutical industry as “Excellent” or “Good”, propelling the industry higher in the ranking compared to biotech, medical devices, retail pharmacies, generics and to insurance companies, as well as private sector health services. The figure also represents a significant improvement over 2020, when only 56% of Italian patient groups rated the industry's corporate reputation as “Excellent” or “Good”.
Italy edition: the corporate reputation of pharma in 2021
